Research programme: anti-osteopontin polyclonal antibody - The Feinstein Institute for Medical ResearchAlternative Names: anti-OPN Ab - The Feinstein Institute for Medical Research
Latest Information Update: 28 Apr 2015
At a glance
- Originator The Feinstein Institute for Medical Research
- Class Glycoproteins; Polyclonal antibodies
- Mechanism of Action Osteopontin antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sepsis